Previous Close | 43.99 |
Open | 44.16 |
Bid | 43.87 x 1100 |
Ask | 43.88 x 1400 |
Day's Range | 43.78 - 44.62 |
52 Week Range | 43.33 - 69.10 |
Volume | |
Avg. Volume | 15,803,131 |
Market Cap | 88.99B |
Beta (5Y Monthly) | 0.39 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 2.40 (5.46%) |
Ex-Dividend Date | Apr 04, 2024 |
1y Target Est | N/A |
PRINCETON, N.J., May 06, 2024--U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)
PRINCETON, N.J., May 06, 2024--European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line....
Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseasesCAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced a two-year extension to the collaboration with Bristol Myers Squibb (NYSE: BMY) under which the parties may research, develop, and commercialize autologous and allogeneic alpha-beta T cell medicines for the treatment of cancer